Vertex SME Holdings Limited, a private equity vehicle managed by JMMB Securities Limited, is gearing up to raise another $1 billion to fund its pipeline of investment opportunities. Private equity ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs ...

Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...

Vertex had plans to hire 1,300 employees in Wilmington, but it never even got close.

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped.

Is Vertex stock a buy? Vertex's share price is still in positive territory year to date despite today's pullback.

Vertex reported Q1 revenue and earnings that fell well short of what most investors were anticipating. Higher costs were primarily responsible for the hit to earnings. Despite the headwinds ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.

Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis ...

Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration.

CRISPR treatment for sickle cell disease carries a high risk of infertility. Vertex wants to preserve patient fertility, but a federal rule poses problems.